157 related articles for article (PubMed ID: 33201085)
1. Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes.
van Dongen JM; Jornada Ben Â; Finch AP; Rossenaar MMM; Biesheuvel-Leliefeld KEM; Apeldoorn AT; Ostelo RWJG; van Tulder MW; van Marwijk HWJ; Bosmans JE
Med Care; 2021 Jan; 59(1):82-90. PubMed ID: 33201085
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
3. Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index.
Franklin M; Hunter RM; Enrique A; Palacios J; Richards D
Value Health; 2022 Jun; 25(6):1018-1029. PubMed ID: 35667775
[TBL] [Abstract][Full Text] [Related]
4. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
[TBL] [Abstract][Full Text] [Related]
5. To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study.
Ben ÂJ; van Dongen JM; Finch AP; Alili ME; Bosmans JE
Eur J Health Econ; 2023 Nov; 24(8):1253-1270. PubMed ID: 36371791
[TBL] [Abstract][Full Text] [Related]
6. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.
Mulhern B; Feng Y; Shah K; Janssen MF; Herdman M; van Hout B; Devlin N
Pharmacoeconomics; 2018 Jun; 36(6):699-713. PubMed ID: 29476363
[TBL] [Abstract][Full Text] [Related]
7. An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis.
Wailoo A; Alava MH; Pudney S; Barton G; O'Dwyer J; Gomes M; Irvine L; Meads D; Sadique Z
Value Health; 2021 Apr; 24(4):568-574. PubMed ID: 33840435
[TBL] [Abstract][Full Text] [Related]
8. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
Cheung PWH; Wong CKH; Cheung JPY
Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
[TBL] [Abstract][Full Text] [Related]
9. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of total disc replacement versus multidisciplinary rehabilitation in patients with chronic low back pain: a Norwegian multicenter RCT.
Johnsen LG; Hellum C; Storheim K; Nygaard ØP; Brox JI; Rossvoll I; Rø M; Andresen H; Lydersen S; Grundnes O; Pedersen M; Leivseth G; Olafsson G; Borgström F; Fritzell P;
Spine (Phila Pa 1976); 2014 Jan; 39(1):23-32. PubMed ID: 24150435
[TBL] [Abstract][Full Text] [Related]
12. Mapping Sri Lankan EQ-5D-3L to EQ-5D-5L Value Sets.
Kularatna S; Chen G; Byrnes J; Scuffham PA
Value Health Reg Issues; 2017 May; 12():20-23. PubMed ID: 28648311
[TBL] [Abstract][Full Text] [Related]
13. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
14. Patient versus general population health state valuations: a case study of non-specific low back pain.
van Dongen JM; van denBerg B; Bekkering GE; van Tulder MW; Ostelo RWJG
Qual Life Res; 2017 Jun; 26(6):1627-1633. PubMed ID: 28155048
[TBL] [Abstract][Full Text] [Related]
15. Can EQ-5D-3L utility values of low back pain patients be validly predicted by the Oswestry Disability Index for use in cost-effectiveness analyses?
Pellekooren S; Ben ÂJ; Bosmans JE; Ostelo RWJG; van Tulder MW; Maas ET; Huygen FJPM; Oosterhuis T; Apeldoorn AT; van Hooff ML; van Dongen JM
Qual Life Res; 2022 Jul; 31(7):2153-2165. PubMed ID: 35040002
[TBL] [Abstract][Full Text] [Related]
16. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.
Lien K; Tam VC; Ko YJ; Mittmann N; Cheung MC; Chan KK
Curr Oncol; 2015 Dec; 22(6):e443-52. PubMed ID: 26715881
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
18. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
19. Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe.
Golicki D; Niewada M; Hout BV; Janssen MF; Pickard AS
Value Health Reg Issues; 2014 Sep; 4():19-23. PubMed ID: 29702801
[TBL] [Abstract][Full Text] [Related]
20. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
Noyes K; Dick AW; Holloway RG
Med Decis Making; 2007; 27(3):327-34. PubMed ID: 17502449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
